Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wesley, U. V.
Right arrow Articles by Homoyouni, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wesley, U. V.
Right arrow Articles by Homoyouni, A.
[Cancer Research 65, 1325-1334, February 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

Dipeptidyl Peptidase Inhibits Malignant Phenotype of Prostate Cancer Cells by Blocking Basic Fibroblast Growth Factor Signaling Pathway

Umadevi V. Wesley, Michelle McGroarty and Asal Homoyouni

Department of Microbiology and Molecular Genetics, Vermont Cancer Center, University of Vermont, Burlington, Vermont

Requests for reprints: Umadevi V. Wesley, Department of Microbiology and Molecular Genetics Vermont Cancer Center, University of Vermont, 320B, Stafford Hall, Burlington, VT 05405. Phone: 802-652-2164; Fax: 802-656-8749; E-mail: uwesley{at}zoo.uvm.edu.

Dipeptidyl peptidase IV (DPPIV) is a serine protease with tumor suppressor function. It regulates the activities of mitogenic peptides implied in cancer development. Progression of benign prostate cancer to malignant metastasis is linked to increased production of basic fibroblast growth factor (bFGF), a powerful mitogen. In this study, using in vitro model system we show that DPPIV loss is associated with increased bFGF production in metastatic prostate cancer cells. DPPIV reexpression in prostate cancer cells blocks nuclear localization of bFGF, reduces bFGF levels, inhibits mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)1/2 activation, and decreases levels of urokinase-type plasminogen activator, known downstream effectors of bFGF signaling pathway. These molecular changes were accompanied by induction of apoptosis, cell cycle arrest, inhibition of in vitro cell migration, and invasion. Silencing of DPPIV by small interfering RNA resulted in increased bFGF levels and restoration of mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)1/2 activation. These results indicate that DPPIV inhibits the malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway.

Key Words: DPPIV • Prostate Cancer • bFGF • Motility • Apoptosis




This article has been cited by other articles:


Home page
J EndocrinolHome page
A. J Brennan, J. A Sharp, E. Khalil, M. R Digby, S. L Mailer, C. M Lefevre, and K. R Nicholas
A population of mammary epithelial cells do not require hormones or growth factors to survive
J. Endocrinol., March 1, 2008; 196(3): 483 - 496.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Inamoto, T. Yamada, K. Ohnuma, S. Kina, N. Takahashi, T. Yamochi, S. Inamoto, Y. Katsuoka, O. Hosono, H. Tanaka, et al.
Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors
Clin. Cancer Res., July 15, 2007; 13(14): 4191 - 4200.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
D. J. Drucker
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action
Diabetes Care, June 1, 2007; 30(6): 1335 - 1343.
[Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
I. Kryczek, S. Wei, E. Keller, R. Liu, and W. Zou
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C987 - C995.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. V. Wesley, P. F. Bove, M. Hristova, S. McCarthy, and A. van der Vliet
Airway Epithelial Cell Migration and Wound Repair by ATP-mediated Activation of Dual Oxidase 1
J. Biol. Chem., February 2, 2007; 282(5): 3213 - 3220.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
Y. Zhang, N. Rath, S. Hannenhalli, Z. Wang, T. Cappola, S. Kimura, E. Atochina-Vasserman, M. M. Lu, M. F. Beers, and E. E. Morrisey
GATA and Nkx factors synergistically regulate tissue-specific gene expression and development in vivo
Development, January 1, 2007; 134(1): 189 - 198.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Ghersi, Q. Zhao, M. Salamone, Y. Yeh, S. Zucker, and W.-T. Chen
The Protease Complex Consisting of Dipeptidyl Peptidase IV and Seprase Plays a Role in the Migration and Invasion of Human Endothelial Cells in Collagenous Matrices.
Cancer Res., May 1, 2006; 66(9): 4652 - 4661.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Xiao, D. Chinnappan, R. Pestell, C. Albanese, and H. C. Weber
Bombesin Regulates Cyclin D1 Expression through the Early Growth Response Protein Egr-1 in Prostate Cancer Cells
Cancer Res., November 1, 2005; 65(21): 9934 - 9942.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.